Real‐world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors

医学 耐受性 不利影响 血友病 药物警戒 恶心 儿科 队列 上市后监督 内科学
作者
Eman Hassan,Lancashire Jonathan,Motwani Jayashree
出处
期刊:Haemophilia [Wiley]
卷期号:27 (6) 被引量:16
标识
DOI:10.1111/hae.14432
摘要

Abstract Background Emicizumab is a bispecific monoclonal antibody that bridges activated factor (F) IX and FX, and maintains haemostasis in patients with haemophilia A (PwHA). As a novel agent, many questions remain unanswered about the loss of emicizumab efficacy due to anti‐drug antibody (ADA) development, the incidence of inhibitor recurrence in previously tolerized patients, and the risk of de novo inhibitor development. Aim To present real‐world experience regarding tolerability, side effects, and outcomes of adverse events of emicizumab prophylaxis in paediatric PwHA. Methods Data on tolerability, compliance, adverse events, and laboratory results of paediatric patients receiving emicizumab prophylaxis, treated at the Haemophilia Comprehensive Care Centre, at Birmingham Children's Hospital between March 2018 and June 2021, were collected. Results Our results showed that out of 52 patients, four experienced minor adverse events, two developed headaches, one developed abdominal pain and nausea, and one developed injection site reactions. Moreover, four patients experienced major adverse events, including severe headaches, major bleeding events, development of ADAs, and recurrence of inhibitors. Emicizumab prophylaxis was discontinued in three patients (5.7% of the cohort) due to adverse events. In addition, emicizumab was discontinued in one patient because of poor compliance. No adverse events were reported in previously untreated/minimally treated patients, represented by four patients in our cohort. Conclusions The real‐world experience of emicizumab prophylaxis in our cohort showed that emicizumab was safe and well tolerated in paediatric PwHA with and without inhibitors. Long‐term assessment is crucial to monitor major adverse events, recurrence of inhibitors, and development of ADAs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
传奇3应助Cml采纳,获得10
刚刚
jiang完成签到,获得积分10
1秒前
2秒前
牛文文发布了新的文献求助10
2秒前
可爱的函函应助lcr采纳,获得10
3秒前
科研达人发布了新的文献求助30
5秒前
RogerCqz完成签到 ,获得积分10
6秒前
7秒前
jiang发布了新的文献求助10
7秒前
圆锥香蕉应助科研通管家采纳,获得20
8秒前
怕黑半仙应助科研通管家采纳,获得10
8秒前
8秒前
圆锥香蕉应助科研通管家采纳,获得20
8秒前
科研通AI5应助科研通管家采纳,获得10
8秒前
8秒前
领导范儿应助科研通管家采纳,获得10
8秒前
9秒前
9秒前
Cml完成签到,获得积分10
10秒前
Liufgui应助牛文文采纳,获得10
11秒前
chun发布了新的文献求助10
12秒前
YI应助南兮采纳,获得10
12秒前
orixero应助颜云尔采纳,获得10
13秒前
anna发布了新的文献求助10
13秒前
YWang发布了新的文献求助10
16秒前
16秒前
NiNi完成签到,获得积分10
18秒前
悦耳寒松发布了新的文献求助10
18秒前
sijing发布了新的文献求助10
19秒前
7777完成签到,获得积分10
19秒前
求求了,让孩子毕业吧完成签到,获得积分10
20秒前
20秒前
23秒前
我是老大应助LiuJinhui采纳,获得10
24秒前
27秒前
量子星尘发布了新的文献求助10
27秒前
清久完成签到,获得积分10
28秒前
牛马码字员完成签到,获得积分10
28秒前
橙果果发布了新的文献求助20
29秒前
所所应助11采纳,获得10
29秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989069
求助须知:如何正确求助?哪些是违规求助? 3531351
关于积分的说明 11253589
捐赠科研通 3269939
什么是DOI,文献DOI怎么找? 1804851
邀请新用户注册赠送积分活动 882074
科研通“疑难数据库(出版商)”最低求助积分说明 809073